Patent 11965163 was granted and assigned to MiNA Therapeutics on April, 2024 by the United States Patent and Trademark Office.
The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.